Advertisement
Letter to the Editor| Volume 50, ISSUE 3, P232-235, June 2008

Download started.

Ok

The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

      Summary

      The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miles E.A.
        • Bakewell L.
        • Calder P.C.
        Production of lymphocyte-derived cytokines by whole umbilical cord blood cultures stimulated with mitogens and allergens.
        Cytokines. 2003; 21: 74-83
        • Seneviratne S.L.
        • Jones L.
        • Bailey A.S.
        • Black A.P.
        • Ogg G.S.
        Severe atopic dermatitis is associated with a reduced frequency of IL-10 producing allergen-specific CD4+ T cells.
        Clin Exp Dermatol. 2006; 31: 689-694
        • Gardner L.M.
        • Thien F.C.
        • Douglass J.A.
        • Rolland J.M.
        • O’Hehir R.E.
        Induction of T “regulatory” cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers.
        Clin Exp Allergy. 2004; 34: 1209-1219
        • Akdis M.
        • Verhagen J.
        • Taylor A.
        • Karamloo F.
        • Karagiannidis C.
        • Crameri R.
        • et al.
        Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells.
        J Exp Med. 2004; 199: 1567-1575
        • Sakamoto T.
        • Miyazaki E.
        • Aramaki Y.
        • Arima H.
        • Takahashi M.
        • Kato Y.
        • et al.
        Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC̃Nga mice.
        Gene Therapy. 2004; 11: 317-324
        • Kalechman Y.
        • Gafter U.
        • Weinstein T.
        • Chagnac A.
        • Freidkin I.
        • Tobar A.
        • et al.
        Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3.
        J Biol Chem. 2004; 4: 24724-24732
        • Sredni B.
        • Tichler T.
        • Shani A.
        • Catane R.
        • Kaufman B.
        • Strassmann G.
        • et al.
        Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.
        J Natl Cancer Inst. 1996; 88: 1276-1284
        • Hanifin J.M.
        • Rajka G.
        Diagnostic features of atopic dermatitis.
        Acta Dermatol Venereol. 1980; 92: 44-47
        • Veiopoulou C.
        • Kogopoulou O.
        • Tzakos E.
        • Mavrothalassitis G.
        • Mitsias D.
        • Karafoulidou A.
        • et al.
        Thyphronitis G. IL-2 and IL-10 production by human CD4+ T cells is differentially regulated by p38: mode of stimulation-dependent regulation of IL-2.
        Neuroimmunomodulation. 2004; 11: 199-208
        • Lester M.R.
        • Hofer M.F.
        • Gately M.
        • Trumble A.
        • Leung D.Y.M.
        Down regulation effects of IL-4 and IL-10 on the IFNγ response in Atopic dermatitis.
        J Immunol. 1995; 154: 6174-6181